1400997-37-6

Basic information

• Product Name: (RS)-[2-(4-bromo-3-fluorophenyl)-2-hydroxyethyl]-(2-hydroxyethyl)carbamic acid tert-butyl ester
• Synonyms: (RS)-[2-(4-bromo-3-fluorophenyl)-2-hydroxyethyl]-(2-hydroxyethyl)carbamic acid tert-butyl ester
• CAS NO: 1400997-37-6
• Molecular Weight: 378.238
• Mol File: 1400997-37-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (RS)-[2-(4-bromo-3-fluorophenyl)-2-hydroxyethyl]-(2-hydroxyethyl)carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (RS)-[2-(4-bromo-3-fluorophenyl)-2-hydroxyethyl]-(2-hydroxyethyl)carbamic acid tert-butyl ester(1400997-37-6)
• EPA Substance Registry System: (RS)-[2-(4-bromo-3-fluorophenyl)-2-hydroxyethyl]-(2-hydroxyethyl)carbamic acid tert-butyl ester(1400997-37-6)

Safety Data

• Hazardous Substances Data: 1400997-37-6(Hazardous Substances Data)

Upstream product

• 1003879-02-4 2-bromo-1-(4-bromo-3-fluorophenyl)ethanone 
• 695188-21-7 4-bromo-3-fluorobenzoyl chloride 
• 1400997-35-4 (RS)-2-(4-bromo-3-fluorophenyl)-oxirane 
• 1260857-14-4 2-chloro-1-(4-bromo-3-fluorophenyl)-ethanone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1400997-36-5 (RS)-1-(4-bromo-3-fluorophenyl)-2-(2-hydroxyethylamino)-ethanol 

Downstream Products

• 1400995-94-9 (RS)-(5-ethoxy-pyrimidin-2-yl)-(2-fluoro-4-morpholin-2-yl-phenyl)-amine 
• 1400997-39-8 (RS)-2-[4-(benzhydrylideneamino)-3-fluorophenyl]-morpholine-4-carboxylic acid tert-butyl ester 
• 1400997-42-3 (RS)-2-[4-(5-ethoxy-pyrimidin-2-ylamino)-3-fluoro-phenyl]-morpholine-4-carboxylic acid tert-butyl ester 
• 1400997-56-9 (RS)-2-[3-Fluoro-4-(5-trifluoromethyl-pyrimidin-2-ylamino)-phenyl]-morpholine-4-carboxylic acid tert-butyl ester 
• 1400995-90-5 (RS)-5-chloro-N-(2-fluoro-4-(morpholin-2-yl)phenyl)pyrimidin-2-amine 
• 1400996-15-7 (RS)-(2-fluoro-4-morpholin-2-yl-phenyl)-(5-trifluoromethyl-pyrimidin-2-yl)-amine 
• 1400997-38-7 (RS)-2-(4-bromo-3-fluorophenyl)-morpholine-4-carboxylic acid tert-butyl ester 
• 1400997-40-1 (RS)-2-(4-amino-3-fluorophenyl)-morpholine-4-carboxylic acid tert-butyl ester 
• 1400997-41-2 tert-butyl (RS)-2-(4-(5-chloropyrimidin-2-ylamino)-3-fluorophenyl)morpholine-4-carboxylate 
• 1400997-48-9 (-)-(S)-2-(4-amino-3-fluorophenyl)-morpholine-4-carboxylic acid tert-butyl ester 
• 1400997-47-8 (+)-(R)-2-(4-amino-3-fluorophenyl)-morpholine-4-carboxylic acid tert-butyl ester 
• 1447831-80-2 tert-butyl 2-(4-cyano-3-fluorophenyl)morpholine-4-carboxylate 
• 1447831-82-4 tert-butyl 2-(3-(4-fluorobenzamido)-1H-indazol-6-yl)morpholine-4-carboxylate 
• 1415758-93-8 (S)-tert-butyl 2-(4-(1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carboxamido)-3-fluorophenyl)morpholine-4-carboxylate 

Relevant articles and documents

PYRAZINE DERIVATIVES

The present invention relates to compounds of formula (I), wherein R1R2 are hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl, OCH2-cycloalkyl or heterocycloalkyl which is optionally substituted by halogen, with the proviso that one of R1 and R2 is hydrogen, or R1 and R2 form together with the carbon atom to which they are attach a phenyl ring, which may be optionally substituted by lower alkyl; R3/R4 are hydrogen, halogen or cyano; with the proviso that one of R3 and R4 is hydrogen; or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

HETEROCYCLIC AMINE DERIVATIVES

The present invention relates to compounds of formula I wherein A, B, X, Y, Ar, R1, R2, R′, m and n are as defined herein and to pharmaceutical active acid addition salts thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

SUBSTITUTED BENZAMIDE DERIVATIVES

The present invention relates to compounds of formula wherein R1, R2, R3, X, Z, Ar, and n are as described in the claims, Ar is phenyl or heteroaryl, selected from the group consisting of 1H-indazole-3yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, pyrimidine-5-yl, 1H-pyrazole-3-yl, 1H-pyrazole-4-yl and 1H-pyrazole-5-yl; or to a pharmaceutically suitable acid addition salt thereof, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.